Geographic Atrophy

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.

Discover how ellipsoid zone integrity predicts geographic atrophy growth rates in recent clinical trials, enhancing future treatment strategies.

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and future directions in ophthalmology.

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.